Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.45 |
| ▸ | DRD4 | P21917 | 4/20 | 0.45 |
| ▸ | DRD3 | P35462 | 4/20 | 0.45 |
| ▸ | HTR5A | P47898 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 11/20 | 0.42 |
| ▸ | PPARA | Q07869 | 4/20 | 0.42 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | DRD5 | P21918 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3949854 | 1.00 | DRD2 (0.45) | DRD2DRD4DRD3HTR5APPARD | |
| SCHEMBL27669707 | 0.91 | DRD2 (0.44) | DRD2DRD4DRD3HTR5APPARD | |
| SCHEMBL4497378 | 0.81 | PPARD (0.51) | PPARDPPARA | |
| SCHEMBL3957347 | 0.81 | PPARD (0.51) | PPARDPPARA | |
| SCHEMBL27669725 | 0.80 | DRD2 (0.43) | DRD2DRD4DRD3HTR5ADRD1 | |
| SCHEMBL27669722 | 0.80 | DRD2 (0.43) | DRD2DRD4DRD3HTR5ADRD1 | |
| SCHEMBL27669706 | 0.80 | DRD2 (0.46) | DRD2DRD4DRD3HTR5ADRD1 | |
| SCHEMBL3954189 | 0.77 | PPARD (0.49) | PPARDPPARA | |
| SCHEMBL3947555 | 0.76 | PPARD (0.65) | PPARDPPARA | |
| SCHEMBL2123255 | 0.76 | DRD2 (0.39) | DRD2DRD4DRD3HTR5ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605171-B2 | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists | MERCK & CO., INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080249093-A1 | (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists | MERCK & CO., INC. (US) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249093-A1 | (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists | S1PR1, S1PR3, S1PR5 | DRD2 2158/4885DRD4 2655/4885DRD3 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.